Real-World Use of Letermovir and Maribavir for CMV Prophylaxis and Treatment in Solid Organ Transplant Recipients: Clinical Outcomes and Resistance Patterns From a Dual-Center Cohort. (PubMed, Pharmacotherapy) - Dec 24, 2025 - "LET was effective for PP but associated with frequent breakthroughs in SP patients. MBV was limited by incomplete viral suppression and emergent resistance. These findings highlight the variable effectiveness of LET and MBV in clinical practice and support the need for further research to define optimal antiviral use in SP and refractory CMV treatment."
Clinical data • Journal • Real-world evidence • Cytomegalovirus Infection • Infectious Disease • Solid Organ Transplantation • Transplantation
|
|
Alissa Wright; Allison Mah; Casara Hong; Christopher Lowe; Man Ting Xu; Nancy Matic; Sara Belga; Wan-Yun Polinna Tsai
|